"With Rexin-G™, Epeius is advancing genetic medicine worldwide. Our technology offers new treatment options for many cancer patients who are refractory to conventional chemotherapy treatment regimens," said Erlinda Maria Gordon, M.D, Vice President of Operations and Medical Affairs of Epeius Biotechnologies.
"Our preclinical and clinical data show that Rexin-G™ has a favorable safety profile without the serious side effects generally associated with chemotherapy."
Developed by Epeius Biotechnologies, Rexin-G™ is designed to target primary and metastatic cancers, while limiting side effects within the body.
Designed to function in the human circulatory system, Rexin-G™ is the only targeted therapy product that can be effectively delivered intravenously.
In the United States, Rexin-G™ is currently under clinical trials for pancreatic cancer, where it has been granted orphan drug status by the USFDA, and in the Philippines for all solid tumors.
Read more at Epeius Biotechnologies.
.jpg)
Comment Preview